Mostrar el registro sencillo del ítem
Non-Classical Effects of FGF23: Molecular and Clinical Features
dc.contributor.author | Martínez Heredia, Luis | |
dc.contributor.author | Canelo-Moreno, Juan Manuel | |
dc.contributor.author | García Fontana, Beatriz | |
dc.contributor.author | Muñoz Torres, Manuel Eduardo | |
dc.date.accessioned | 2024-07-22T10:35:53Z | |
dc.date.available | 2024-07-22T10:35:53Z | |
dc.date.issued | 2024-04-30 | |
dc.identifier.citation | Martínez-Heredia, L.; Canelo-Moreno, J.M.; García-Fontana, B.; Muñoz-Torres, M. Non-Classical Effects of FGF23: Molecular and Clinical Features. Int. J. Mol. Sci. 2024, 25, 4875. [https://doi.org/10.3390/ijms25094875] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/93359 | |
dc.description.abstract | This article reviews the role of fibroblast growth factor 23 (FGF23) protein in phosphate metabolism, highlighting its regulation of vitamin D, parathyroid hormone, and bone metabolism. Although it was traditionally thought that phosphate–calcium homeostasis was controlled exclusively by parathyroid hormone (PTH) and calcitriol, pathophysiological studies revealed the influence of FGF23. This protein, expressed mainly in bone, inhibits the renal reabsorption of phosphate and calcitriol formation, mediated by the α-klotho co-receptor. In addition to its role in phosphate metabolism, FGF23 exhibits pleiotropic effects in non-renal systems such as the cardiovascular, immune, and metabolic systems, including the regulation of gene expression and cardiac fibrosis. Although it has been proposed as a biomarker and therapeutic target, the inhibition of FGF23 poses challenges due to its potential side effects. However, the approval of drugs such as burosumab represents a milestone in the treatment of FGF23-related diseases. | es_ES |
dc.description.sponsorship | Institute of Health Carlos III grant (PI22/00726) co-funded by the European Regional Development Fund (FEDER) | es_ES |
dc.description.sponsorship | LM-H and BG-F are funded by CIBER of Frailty and Healthy Aging (CIBERFES;CB16/10/00475) and by Institute of Health Carlos III grant (CP22/00022) respectively. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | FGF23 | es_ES |
dc.subject | Klotho | es_ES |
dc.subject | Calcineurin pathway | es_ES |
dc.title | Non-Classical Effects of FGF23: Molecular and Clinical Features | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/ijms25094875 | |
dc.type.hasVersion | VoR | es_ES |